Need for Genetic Testing and Genetic Counseling in Hereditary Breast Cancer
DOI:
https://doi.org/10.48111/2021.02.07Keywords:
Breast cancer, BRCA1 & BRCA2, genetic testing, genetic counseling, screeningAbstract
Breast cancer is the commonest cancer among women and in many instances, it has a hereditary predisposition also. The commonest known genes associated with the familial predisposition of breast cancer are mutated BRCA1 and BRCA 2 which are located on chromosomes 17 & 13 respectively and are inherited in autosomal dominant fashion. All individuals suspected of having a familial predisposition for breast cancer should be subjected to genetic counseling, screening, and testing for BRCA 1&2 genes and if they come out to be positive then their relatives should be counseled and tested too so that safe surveillance and management options can be offered to them.
References
Ataollahi MR, Sharifi J, Paknahad MR, Paknahad A. Breast cancer and associated factors: a review. J Med Life. 2015;8(Spec Iss 4):6-11.
Ellsworth RE, Decewicz DJ, Shriver CD, Ellsworth DL. Breast cancer in the personal genomics era. Curr Genomics. 2010;11(3):146-161. doi:10.2174/138920210791110951
Shiovitz S, Korde LA. Genetics of breastcancer: a topic in evolution. Ann Oncol. 2015;26(7):1291-1299. doi:10.1093/annonc/mdv022 .
Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; September 4, 1998.
Grindedal EM, Heramb C, Karsrud I, et al. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer. 2017;17(1):438. Published 2017 Jun 21. doi:10.1186/s12885-017-3422-2
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Recommendation Statement. Am Fam Physician. 2020;101(4):233-238.
Pal T, Vadaparampil ST. Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control. 2012;19(4):255-266. doi:10.1177/107327481201900402
Panchal SM, Ennis M, Canon S, Bordeleau LJ. Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet. 2008;9:116. Published 2008 Dec 22. doi:10.1186/1471-2350-9-116
Agnese DM, Pollock RE. Breast Cancer Genetic Counseling: A Surgeon's Perspective. Front Surg. 2016;3:4. Published 2016 Jan 28. doi:10.3389/fsurg.2016.00004
Manahan ER, Kuerer HM, Sebastian M, et al. Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025-3031. doi:10.1245/s10434-019-07549-8
Scherr CL, Lindor NM, Malo TL, Couch FJ, Vadaparampil ST. Genetic counselors' practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing. Clin Genet. 2015;88(6):523-529. doi:10.1111/cge.12563
Willoughby A, Andreassen PR, Toland AE. Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer. J Pers Med. 2019;9(1):15. Published 2019 Mar 1. doi:10.3390/jpm9010015
Conley CC, Ketcher D, Reblin M, et al. The big reveal: Family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer. J Genet Couns. 2020;29(3):410-422. doi:10.1002/jgc4.1196
Kotsopoulos J. BRCA Mutations and Breast Cancer Prevention. Cancers (Basel). 2018;10(12):524. Published 2018 Dec 19. doi:10.3390/cancers10120524
Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017;4(1):10.15761/ICST.1000228. doi:10.15761/ICST.1000228
Metcalfe KA, Dennis CL, Poll A, et al. Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial. Genet Med. 2017;19(3):330-336. doi:10.1038/gim.2016.108
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Tooba Mahmud
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
